Search the Newsreel

Shanthi Gears Ltd. Share Price: Near Low, What Data Shows

Why is Neonc Technologies stock surging today?

Neonc Technologies Holdings Inc. stock surged 11.3% in pre-open trading after its Phase 2a NEO100-01 study met its primary endpoint with a statistically significant six-month progression-free survival rate. The surge was amplified by the stock trading near its 52-week low, a tight float, high …

NeOnc Technologies Holdings, Inc. Common Stock (NASDAQ: NTHI) Stock Price, News & Analysis

This article provides an overview of NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) stock, including its current price, daily range, and trading volume. It also lists key fundamental data such as previous close, market cap, and P/E ratio, while noting several financial metrics are currently …

NeOnc Technologies Holdings Reports Positive Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

NeOnc Technologies Holdings announced positive Phase 2a results for its intranasal NEO100 therapy in recurrent IDH1-mutant high-grade glioma, showing a six-month progression-free survival rate of 48.9%, significantly exceeding the 20% benchmark. The study also reported a median overall survival of 26.09 months and a …

NeOnc Technologies Reports Positive Phase 2a NEO100 Results; Median OS 26.09 Months, PFS-6 48.9%

NeOnc Technologies reported positive topline results from its Phase 2a study of intranasal NEO100, showing a median overall survival of 26.09 months and a six-month progression-free survival (PFS-6) of 48.9%, significantly exceeding the 20% protocol benchmark. The treatment was well tolerated with low-grade adverse …

Five of 24 glioma patients remain on NeOnc’s at-home nasal therapy

NeOnc Technologies reported positive topline Phase 2a results for its intranasal NEO100 therapy in patients with recurrent IDH1-mutant high-grade glioma, meeting its primary endpoint with a six-month progression-free survival of 48.9%. The therapy showed encouraging median overall survival of 26.09 months and was well-tolerated …

NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence

NeOnc Technologies Holdings (NASDAQ: NTHI) is anticipated to release topline Phase 2a results for its intranasal NEO100 therapy for recurrent IDH1-mutant high-grade glioma on August 12. Market observers are noting a "triple confluence setup" for a potential high-impact catalyst, considering the stock's recent 52-week …

$NeOnc Technologies (NTHI.US)$@Trytosaveabit and thats 10% ROI! thanks for the heads-up! [Cool Guy]

A user named AigooHensemboi thanks another user, Trytosaveabit, for a heads-up on NeOnc Technologies (NTHI.US), which resulted in a 10% return on investment (ROI). The post is a brief message from the Moomoo community feed, highlighting a positive trading outcome.

NeOnc to present phase 2a NEO100 trial results on Tuesday By Investing.com

NeOnc Technologies Holdings Inc. (NASDAQ:NTHI) is set to announce topline results from its phase 2a study of intranasal NEO100 for recurrent IDH1-mutant high-grade glioma on Tuesday, with an investor call scheduled for August 12, 2026. The company reported a net loss of $14.2 million …

NEONC TECHNOLOGIES HOLDINGS, INC. Q2 2026: Revenue $0 EPS $(0.58) — 10-Q Summary

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) reported its Q2 2026 financial results, with revenue of $0 and a net loss of $(14.24M), resulting in a diluted loss per share of $(0.58). Despite the financial loss, the company highlighted significant clinical progress, pipeline expansion for NEO212, …

NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout

NeOnc Technologies Holdings, Inc. announced its financial results for the second quarter ended June 30, 2026, highlighting significant clinical and regulatory advancements for its NEO100 and NEO212 programs. The company confirmed that topline results from its Phase 2a NEO100 study in recurrent IDH1-mutant high-grade …

NeOnc Technologies (NTHI) raises $20M but warns on going concern

NeOnc Technologies Holdings, Inc. (NTHI) reported a net loss of $23.1 million for the first six months of 2026, alongside an accumulated deficit of $135.8 million, raising substantial doubt about its ability to continue as a going concern. Despite raising approximately $20 million through …

NTHI Stock Price and Chart — NASDAQ:NTHI

This article provides an overview of NeOnc Technologies Holdings, Inc. (NTHI) stock, including its current price, market capitalization, key financial metrics, and analyst forecasts. It highlights the company's status as a clinical-stage biopharmaceutical company developing novel technology for central nervous system diseases. The article …

NeOnc Technologies Holdings Inc (NTHI) Stock News Today

This article provides current stock information for NeOnc Technologies Holdings Inc (NTHI), including its stock price, market cap, and a note that more news will be available soon. It highlights that the company's stock is trading at $3.500 with no change and has a …

NTHI PE Ratio & Valuation, Is NTHI Overvalued

This article analyzes the valuation of NeOnc Technologies Holdings Inc (NTHI), stating that its current forward PS ratio places it in the "Fair zone" compared to its five-year average. It highlights the company's Price-to-Book ratio of -6.84 and a Forward Free Cash Flow yield …

Shanthi Gears passes all 53rd AGM resolutions with near-unanimous support

Shanthi Gears publishes Q1FY27 results in newspapers after 56% profit fall

NeOnc Technologies Holdings, Inc. Revenue Breakdown – NASDAQ:NTHI

NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) generated $40,000 USD in revenue last year, primarily from its Biotechnology segment. The United States was the largest contributor to its revenue. This represents a decrease from the previous year's revenue of $83,000 USD.

NeOnc appoints Nasim Shomali to board of directors

NeOnc Technologies Holdings, Inc. has appointed Nasim Shomali to its board of directors, effective July 1. Shomali brings over a decade of experience in corporate strategy, financial planning, and operating models, having previously served as a Strategy Executive at Accenture. NeOnc is a clinical-stage …

NeOnc Technologies Holdings Inc

This article provides a brief overview of NeOnc Technologies Holdings Inc (NTHI) from TradingKey. It highlights the company's stock price, market capitalization, and the current unavailability of detailed revenue breakdown information by business segment or region. The stock closed at 3.430 USD, down 5.51%.

NeOnc Technologies Holdings Inc (NTHI) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for NeOnc Technologies Holdings Inc (NTHI). It notes that NTHI has not distributed any dividends over the past five years. The page also includes current stock pricing and market capitalization details for NTHI.

NeOnc Technologies Holdings Inc (NTHI) Institutional Confidence

This article provides an "Institutional Confidence" score for NeOnc Technologies Holdings Inc (NTHI), which is 3.00, unchanged from its previous score. It details the institutional shareholdings and recent shareholder activity for several entities, including Chen (Thomas C.), AFH Holding & Advisory, L.L.C., and HighPoint …

NeOnc Technologies Holdings Inc (NTHI) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for NeOnc Technologies Holdings Inc (NTHI), highlighting its current earnings forecast score and industry ranking. Based on analysis from 3 analysts, the stock has a "Buy" rating with a significant upside space for its target price. The article …

NTHI|NeOnc Technologies Holdings Inc|Price:3.420|Chg%:-0.210

NeOnc Technologies Holdings Inc (NTHI) is a clinical-stage biopharmaceutical company focused on treatments for intracranial malignancies, developing lead products NEO100 and NEO212. Analyst ratings suggest a "Buy" with a target price of $16.00, indicating a significant upside, despite the stock's recent weak performance. The …

Enterprise value to EBITDA forward of NeOnc Technologies Holdings, Inc. – NASDAQ:NTHI

This article provides the enterprise value to EBITDA forward for NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). It appears to be a financial data point from TradingView, indicating a specific metric for the company's valuation. The content itself seems to be a display of this …

NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition

NeOnc Technologies Holdings, Inc. announced receipt of detailed written feedback from the FDA regarding the chemistry, manufacturing and controls (CMC) development program for its drug NEO212, and the planned transition from a capsule to a tablet formulation. The feedback clarifies requirements for late-stage development, …

NEONC TECHNOLOGIES - TO UPDATE NEO212 DEVELOPMENT PLAN AFTER INCORPORATING FDA FEEDBACK

NEONC Technologies plans to update its NEO212 development plan following feedback from the FDA. This indicates a key regulatory step in advancing their product. The company aims to refine its strategy to align with the FDA's requirements.

Neonc Technologies - Cancels July 9 FDA Meeti

This article provides a brief but critical update regarding Neonc Technologies. The company has announced the cancellation of its previously scheduled FDA meeting on July 9. Further details or implications of this cancellation are not provided in this snippet.

FDA Says NEO212 Drug-Product Plan May Run Alongside Late-Stage Trials

NeOnc Technologies received detailed written feedback from the FDA regarding the chemistry, manufacturing, and controls (CMC) program for its drug, NEO212, which enabled them to cancel their Type B End-of-Phase 1 meeting. The FDA's feedback indicated that the proposed CMC development approach is reasonable …

NeOnc receives FDA CMC feedback on NEO212; capsule-to-tablet bioavailability study advised

NeOnc has received detailed FDA feedback on the Chemistry, Manufacturing, and Controls (CMC) development for NEO212, along with guidance for transitioning from a capsule to a tablet formulation. The FDA found NeOnc's development approach reasonable and recommended an in vivo relative bioavailability study to …

NeOnc Technologies (NASDAQ: NTHI) receives detailed FDA CMC feedback on NEO212

NeOnc Technologies Holdings, Inc. announced it received detailed written feedback from the FDA regarding the chemistry, manufacturing, and controls (CMC) development program for its drug candidate NEO212. The FDA's feedback covers manufacturing, formulation, bioavailability, and the transition from capsule to tablet for late-stage development. …

NeOnc receives FDA feedback on NEO212 manufacturing requirements

NeOnc Technologies Holdings, Inc. received written feedback from the FDA regarding manufacturing requirements for its drug NEO212, streamlining the development process by clarifying chemistry, manufacturing, and controls aspects. Despite recent stock volatility and being near its 52-week low, the FDA's input was deemed sufficiently …

Bullish NeOnc Technologies Holdings Insider Buying Worth US$615.6k Yet To Pay Off

Insiders at NeOnc Technologies Holdings have purchased US$615.6k worth of shares over the past year at an average price of US$5.51, which has since decreased to US$411.4k due to a 15% stock decline. Despite the loss, recent insider buying, particularly US$138k in the last …